Changes in arterial stiffness with comorbidity of COPD–CHD


DOI: https://dx.doi.org/10.18565/therapy.2020.7.83-89

Maychuk E.YU., Voevodina I.V., Vyzhigin D.A.

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Coronary heart disease (CHD) and chronic obstructive pulmonary disease (COPD) are among the leading causes of morbidity and mortality worldwide. The relationship of the cardiovascular and respiratory diseases has been established. This relationship is caused not only by the presence of common risk factors, but also by the general pathophysiological mechanisms of СHD and COPD development. These diseases have a mutual negative effect on the progression of pathologies, treatment effectiveness, quality of life, short-term and long-term outcomes. The literature review provides information on the prevalence and detection of COPD in patients with various forms of IHD, the prevalence and detection of various IHD forms in patients with COPD and general mechanisms for the development of these pathologies. A separate problem is the limitation of the instrumental studies possibilities: spirometry, plethysmography – in patients with СHD and coronary angiography in patients with COPD. Non-invasive simple economical methods are the most promising for use in clinical practice. In this aspect, the measurement of arterial stiffness is of particular interest an integral indicator that is changed under the influence of pathophysiological mechanisms acting in patients with COPD and IHD. Evaluation of arterial stiffness parameters seems to be an affordable method that can help the clinician to suspect changes in the vascular bed and take measures to prevent the development of cardiovascular events.
Keywords: coronary heart disease, chronic obstructive pulmonary disease, arterial stiffness, pulse wave velocity, inflammation
Read entire article

Literature


  1. Rabe K.F., Hurst J.R., Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018; 27(149): 180057. doi: 10.1183/16000617.0057-2018.

  2. Global initiative for obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 report). https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf.

  3. Campo G., Pavasini R., Malagu M. et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: Overview of mechanisms and clinical management. Cardiovasc Drugs Ther. 2015; 29(2): 147–57. doi: 10.1007/s10557-014-6569-y.

  4. Stefan M.S., Bannuru R.R., Lessard D. et al. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest. 2012; 141: 1441–48. doi: 10.1378/chest.11-2032.

  5. Warnier M.J., Rutten F.H., Numans M.E. et al. Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. COPD. 2013; 10: 62–71. doi: 10.1007/978-3-319-11776-8_64.

  6. Franssen F.M.E., Soriano J.B., Roche N. et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016; 194(5): 568–76. doi: 10.1164/rccm.201512-2480OC.

  7. Almagro P., Lapuente A., Pareja J. et al. Underdiagnosis and prognosis of chronic Obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis. 2015; 10: 1353–61. doi: 10.2147/COPD.S84482.

  8. Hadi H.A., Zubaid M., Al Mahmeed W. et al. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin Cardiol. 2010; 33(4): 228–35. doi: 10.1002/clc.20751.

  9. Mooe T., Stenfors N. The prevalence of COPD in individuals with acute coronary syndrome: a spirometry-based screening study. COPD. 2015; 12(4): 453–61. doi: 10.3109/15412555.2014.974742.

  10. Dreher M., Daher A., Keszei A. et al. Whole-body plethysmography and blood gas analysis in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Respiration. 2019; 97(1): 24–33. doi: 10.1159/000491096.

  11. Reed R.M., Eberlein M., Girgis R.E. et al. Coronary artery disease is under-diagnosed and undertreated in advanced lung disease. Am J Med. 2012; 125(12): 1228.e13–1228.e22. doi: 10.1016/j.amjmed.2012.05.018.

  12. Brekke P.H., Omland T., Holmedal S.H. et al. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J. 2008; 31(3): 563–70. doi: 10.1183/09031936.00015807.

  13. Chang C.L., Robinson S.C., Mills G.D. et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011; 66(9): 764–68. doi: 10.1136/thx.2010.155333.

  14. Lee H.M., Liu M.A., Barrett-Connor E., Wong N.D. Association of lung function with coronary heart disease and cardiovascular disease outcomes in elderly: the Rancho Bernardo study. Respir Med. 2014; 108(12): 1779–85. doi: 10.1016/j.rmed.2014.09.016.

  15. Barnes P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016; 138(1): 16–27. doi: 10.1016/j.jaci.2016.05.011.

  16. Liu Y., Liu X., Lin G. et al. Decreased CD34+ cell number is correlated with cardiac dysfunction in patients with acute exacerbation of COPD. Heart Lung Circ. 2014; 23(9): 875–82. doi: 10.1016/j.hlc.2014.03.008.

  17. Miller J., Edwards L.D., Agusti A. et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013; 107(9): 1376–84. doi: 10.1016/j.rmed.2013.05.001.

  18. Campo G., Pavasini R., Pollina A. et al. Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. Thromb Res. 2013; 132: 151–57. doi: 10.1016/j.thromres.2013.06.007.

  19. Boschetto P., Beghe B., Fabbri L.M., Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012; 17(3): 422–31. doi: 10.1111/j.1440-1843.2011.02118.x.

  20. Zinellu E., Zinellu A., Fois A.G. et al. Circulating biomarkers of oxidative stress in chronic obstructive pulmonary disease: A systematic review. Respir Res. 2016; 17(1): 150. doi: 10.1186/s12931-016-0471-z.

  21. Wang R.T., Li J.Y., Cao Z.G., Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013; 18: 1244–48. doi: 10.1111/resp.12143.

  22. Campo G., Pavasini R., Pollina A. et al. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax. 2014; 69: 80–81. doi: 10.1136/thoraxjnl-2013-203608.

  23. Ekstrom M.P., Hermansson A.B., Strom K.E. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187: 715–20. doi: 10.1164/rccm.201208-1565OC.

  24. Harrison M.T., Short P., Williamson P.A. et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax. 2014; 69(7): 609–15. doi: 10.1136/thoraxjnl-2013-203996.

  25. Violi F., Loffredo L., Carnevale R. et al. Atherothrombosis and oxidative stress: mechanisms and management in elderly. Antioxid Redox Signal. 2017; 27(14): 1083–124. doi: 10.1089/ars.2016.6963.

  26. Bhatt S.P., Dransfield M.T. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res. 2013; 162(4): 237–51. doi: 10.1016/j.trsl.2013.05.001.

  27. Aykan A.C., Gokdeniz T., Boyacı F. et al. Assessment of arterial stiffness in chronic obstructive pulmonary disease by a novel method :cardio-ankle vascular index. Herz. 2014; 39(7): 822–27. doi: 10.1007/s00059-013-3902-3.

  28. Bhatt S.P., Cole A.G., Wells J.M. et al. Determinants of arterial stiffness in COPD. BMC Pulm Med. 2014; 14: 1. doi: 10.1186/1471-2466-14-1.

  29. Undas A., Jankowski M., Kaczmarek P. et al. Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition. Thromb Res. 2011; 128: e24–28. doi: 10.1016/j.thromres.2011.10.017.

  30. Lahousse L., van den Bouwhuijsen Q.J., Loth D.W. et al. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. Am J Respir Crit Care Med. 2013; 187(1): 58–64. doi: 10.1164/rccm.201206-1046OC.

  31. Куценко М.А., Чучалин А.Г. Парадигма коморбидности: синтропия ХОБЛ и ИБС. РМЖ. 2014; 5: 389–392. [Kutsenko M.A., Chuchalin A.G. The paradigm of comorbidity: syntropy of COPD and CHD. Russky meditsinsky zhurnal. 2014; 5: 389–392 (In Russ.)].

  32. Sze M.A., Dimitriu P.A., Hayashi S. et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185(10): 1073–80. doi: 10.1164/rccm.201111-2075OC.

  33. Васюк Ю.А., Иванова С.В., Школьник Е.Л. с соавт. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016; 2: 4–19. [Vasyuk Yu.A., Ivanova S.V., Shkolnik E.L. et al. Consistent opinion of Russian experts on the assessment of arterial stiffness in clinical practice, Kardiovaskulyarnaya terapiya i profilaktika. 2016; 2: 4–19 (In Russ.)]. doi: 10.15829/1728-8800-2016-2-4-19.

  34. Gale N., Albarrati A., Munnery M. et al. Aortic pulse wave velocity as a measure of cardiovascular risk in chronic obstructive pulmonary disease: two-year follow-up data from the ARCADE study. Medicina (Kaunas). 2019; 55(4): 89. doi: 10.3390/medicina55040089.

  35. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55: 1318–27. doi: 10.1093/eurheartj/eht310.P5151.

  36. Patel A.R., Kowlessar B.S., Donaldson G.C. et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 188: 1091–99. doi: 10.1164/rccm.201306-1170OC.

  37. Fisk M., McEniery C.M., Gale N. et al. Surrogate markers of cardiovascular risk and chronic obstructive pulmonary disease. A large case-controlled study. Hypertension. 2018; 71(3): 499–506. doi: 10.1161/hypertensionaha.117.10151.

  38. Fisk M., Cheriyan J., Mohan D. et al. Vascular inflammation and aortic stiffness: potential mechanisms of increased vascular risk in chronic obstructive pulmonary disease. Respir Res. 2018; 19(1): 100. doi: 10.1186/s12931-018-0792-1.


About the Autors

Elena Yu. Maychuk, MD, professor, professor of the Department of hospital therapy No. 1 of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 736-93-49. E-mail: Emaichuk@yandex.ru. ORCID: 0000-0002-0866-785X
Irina V. Voevodina, MD, associate professor, professor of the Department of hospital therapy No. 1 of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 475-90-28. E-mail: Voevodina-1960@mail.ru. ORCID: 0000-0003-2368-0582
Dmitry A. Vyzhigin, first year resident of the Department of hospital therapy No. 1 of A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (926) 680-87-62. E-mail: Dr.vyzhigin@gmail.com. ORCID: 0000-0003-1195-2974

Back to Content

Бионика Медиа